The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.

Under the new framework, Indian tariffs on EU pharmaceutical exports currently at 11 percent and chemicals currently up to 22% will drop to 0 percent for almost all products. Similarly, 90 percent of medical and surgical equipment will see tariffs fall from 27.5 percent to zero.

EU will reciprocate by cutting tariffs on 97.5 percent of India’s chemical exports from 12.8 percent to zero, a move expected to catalyze growth in bulk and specialty chemicals.  Indian pharmaceuticals already enjoy zero duty entry into the EU, but the deal would offer preferential access to the EU pharma market and improved competitiveness for medical devices.

The free flow of pharmaceutical, chemicals and machinery will help India to plug into global supply chain and offers Europe an alternative supply base and market..

EU also clarified that all imports from India to the EU will continue to be subject to the EU’s strict health and product safety rules, with no exception.

On the contentious intellectual property (IP) rights, EU said the agreement also provides a high level of protection and enforcement of IP rights, including with respect to copyright, trademarks, designs, protection of trade secrets and undisclosed information, plant varieties.

Reference:

India-EU FTA to boost pharma, chemicals trade, Indian medical professionals’ credentials to gain acceptance

READ MORE
Exim rebrands as ExSyn: We celebrate our 30-year heritage with a new brand and website that bring alive our values and purpose
News · 27/03/2021

Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.

Biosimilars |  Regulatory Reforms & a Maturing Patent Framework
News · 01/10/2026

A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.

Container Rates Edge Lower Ahead of Golden Week as Suez Traffic Returns
News · 01/10/2026

The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.

In focus: Diacetone Alcohol
Products in focus · 29/09/2026

Diacetone Alcohol (DAA) is an aliphatic hydroxy ketone produced through the base-catalysed aldol addition of two acetone molecules. It contains both ketone and tertiary hydroxyl functionalities, offering excellent solvency and chemical reactivity.

As a high-boiling oxygenated solvent and valuable chemical intermediate, DAA finds broad application in paints and coatings, printing inks, adhesives, industrial cleaning, cosmetics, and textiles. It is also used as an intermediate in the production of mesityl oxide and MIBK. (4-methylpentan-2-one).